by admin | Oct 24, 2022 | press-releases
Home PRESS RELEASE CG Oncology to Present New Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin at SITC 2022 Annual Meeting 💻 DESKTOP AUDIO PLAYER...
by admin | Jun 4, 2022 | press-releases
Home PRESS RELEASE CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...
by admin | May 16, 2022 | press-releases
Home PRESS RELEASE CG Oncology Presents Additional Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin 💻 DESKTOP AUDIO PLAYER ===============================...
by admin | Dec 20, 2021 | press-releases
Home PRESS RELEASE CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of cretostimogene grenadenorepvecin Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin 💻 DESKTOP AUDIO PLAYER ===============================...
by admin | Nov 13, 2021 | press-releases
Home PRESS RELEASE CG Oncology Presents Preliminary Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin 💻 DESKTOP AUDIO PLAYER ===============================...
by admin | Oct 12, 2021 | press-releases
Home PRESS RELEASE CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...